WeTrials
Recruiting

SJiMB21: Phase 2 Study of Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

What is this study?

This study is testing a personalized treatment plan for infants and young children under five years old who have been newly diagnosed with medulloblastoma, a type of brain tumor. Researchers want to see if tailoring treatments based on the specific biological features of each child's tumor can help improve their health and recovery.

Who can participate?

Children between newborn age and nearly 5 years old with a suspected or newly diagnosed medulloblastoma may be able to join. They must have enough tumor sample available for testing and be able to start treatment within 36 days after their first surgery.

What will happen?

Participants will undergo surgery to remove the tumor, followed by a customized plan that may include chemotherapy (medicines that fight cancer), supportive medications, and sometimes radiation therapy. The care team will also provide educational materials to help families understand and navigate the treatment journey.

Where and when?

This study is currently recruiting patients at multiple medical centers, including locations in Palo Alto, California, and Orlando and Tampa, Florida.

Key Points
  • 1Designed specifically for infants and young children with a rare brain tumor.
  • 2Uses customized treatments based on individual tumor biology.
  • 3Currently active and recruiting patients at select medical centers.

Related video

St. Jude: SJiMB21 treatment research for infants with medulloblastoma

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Medulloblastoma

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.